GSK-Vir COVID-19 antibody works as shot in the arm as well as infusion

Published: Updated:
Enable Read mode
100% Font Size

Britain’s GSK and partner Vir said on Friday their antibody-based COVID-19 drug was shown in a trial to work as well when given as a shot in the arm when administered via the standard infusion, potentially offering more convenience.

GSK said it would now speak to global regulators, including the US Food and Drug Administration, about potential approval for the new method of administration, known as intramuscular injection, which can be carried out by family doctors and spare patients a trip to hospital.

For more coronavirus news, visit our dedicated page.

Sotrovimab is authorized for emergency use in the United States to prevent mild or moderate cases of COVID-19 from worsening. The European Medicines Agency has given its go-ahead for use by member states though EU-wide approval is still outstanding.

Similar products are offered or being developed by Eli Lilly , Regeneron and AstraZeneca.

For all the latest headlines follow our Google News channel online or via the app.

Eli Lilly’s therapy is so far given by infusion, or drip, only. AstraZeneca’s antibody drug, under review to possibly prevent infections, is delivered by intramuscular shot only.

Regeneron and Roche’s product can be given as an infusion or injection under the skin, typically in the abdomen.

Read more:

EU authorizes two medicines for people at risk of severe COVID-19

Top Chinese virus expert launches scathing attack on Beijing’s COVID-19 zero push

Moderna seeks EU authorization for COVID-19 vaccine in young kids

Top Content Trending